| 1 |
35388070 | Mismatch repair proteins play a role in ATR activation upon temozolomide treatment in MGMT-methylated glioblastoma. | 2022 Apr 6 |
1 |
| 2 |
35522273 | Temozolomide treatment alters mismatch repair and boosts mutational burden in tumor and blood of colorectal cancer patients. | 2022 May 6 |
1 |
| 3 |
30361254 | Temozolomide Induces Senescence and Repression of DNA Repair Pathways in Glioblastoma Cells via Activation of ATR-CHK1, p21, and NF-κB. | 2019 Jan 1 |
1 |
| 4 |
30867843 | Oncogenic MSH6-CXCR4-TGFB1 Feedback Loop: A Novel Therapeutic Target of Photothermal Therapy in Glioblastoma Multiforme. | 2019 |
2 |
| 5 |
29366782 | Up-regulation of MSH6 is associated with temozolomide resistance in human glioblastoma. | 2018 Feb 19 |
8 |
| 6 |
30217967 | PLK1 Inhibition Targets Myc-Activated Malignant Glioma Cells Irrespective of Mismatch Repair Deficiency-Mediated Acquired Resistance to Temozolomide. | 2018 Dec |
4 |
| 7 |
28831025 | LncRNA-XIST interacts with miR-29c to modulate the chemoresistance of glioma cell to TMZ through DNA mismatch repair pathway. | 2017 Oct 31 |
1 |
| 8 |
28900805 | MGMT and MSH6 immunoexpression for functioning pituitary macroadenomas. | 2017 Dec |
2 |
| 9 |
27446556 | Association of MSH6 mutation with glioma susceptibility, drug resistance and progression. | 2016 Aug |
2 |
| 10 |
25542083 | Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas. | 2015 Mar 28 |
1 |
| 11 |
25646794 | Long-term outcome and MGMT as a predictive marker in 24 patients with atypical pituitary adenomas and pituitary carcinomas given treatment with temozolomide. | 2015 Apr |
1 |
| 12 |
25772801 | The role of temozolomide in the treatment of aggressive pituitary tumors. | 2015 Jun |
1 |
| 13 |
26025730 | Minor Changes in Expression of the Mismatch Repair Protein MSH2 Exert a Major Impact on Glioblastoma Response to Temozolomide. | 2015 Aug 1 |
2 |
| 14 |
23955641 | Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide. | 2014 Mar |
2 |
| 15 |
25078279 | Novel MSH6 mutations in treatment-naïve glioblastoma and anaplastic oligodendroglioma contribute to temozolomide resistance independently of MGMT promoter methylation. | 2014 Sep 15 |
4 |
| 16 |
23057844 | A high frequency of MSH6 G268A polymorphism and survival association in glioblastoma. | 2013 Feb |
4 |
| 17 |
23365123 | DNA mismatch repair protein (MSH6) correlated with the responses of atypical pituitary adenomas and pituitary carcinomas to temozolomide: the national cooperative study by the Japan Society for Hypothalamic and Pituitary Tumors. | 2013 Mar |
3 |
| 18 |
21389894 | A mechanism of acquiring temozolomide resistance during transformation of atypical prolactinoma into prolactin-producing pituitary carcinoma: case report. | 2011 Jun |
2 |
| 19 |
20223108 | The expression of mismatch repair proteins MLH1, MSH2 and MSH6 correlates with the Ki67 proliferation index and survival in patients with recurrent glioblastoma. | 2010 Oct |
1 |
| 20 |
20357518 | Acquired resistance to temozolomide in glioma cell lines: molecular mechanisms and potential translational applications. | 2010 |
1 |
| 21 |
19584161 | MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. | 2009 Jul 15 |
10 |
| 22 |
18676759 | Mismatch repair deficiency does not mediate clinical resistance to temozolomide in malignant glioma. | 2008 Aug 1 |
1 |
| 23 |
17404084 | Loss of the mismatch repair protein MSH6 in human glioblastomas is associated with tumor progression during temozolomide treatment. | 2007 Apr 1 |
6 |